Back

Real-world impact of early quadruple therapy in HFrEF: a comparative analysis of sequential vs. simultaneous approaches

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 3 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Diogo Ferreira

Santa Maria Hospital - CHULN, Lisbon (Portugal)

3 More presentations in this session

Presentation thumbnail
Analysis of the PARAGON-HF study results using win ratio
Doctor W. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial
Doctor A. Foa' (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Feasibility, efficacity and safety of a fast up-titration program of heart failure treatments in real-life practice.
Miss L. Blasi (Toulouse, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Optimizing heart failure management: impact of quadruple therapy initiation at discharge following decompensation events in patients with reduced ejection fraction
thumbnail
Congress Presentation
Predictors of complete evidence-based treatment implementation at hospital discharge of acute heart failure with reduced LVEF in a real-world population
thumbnail
Congress Presentation
Initiation and titration of prognostic drug therapy during hospitalization for acute decompensation of heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources